Patients with Advanced Non–Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials?
Open Access
- 1 January 2016
- journal article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 11 (1), 79-84
- https://doi.org/10.1016/j.jtho.2015.09.006
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non–Small-Cell Lung CancerClinical Lung Cancer, 2015
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisThe Lancet Oncology, 2011
- Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center ExperienceThe Oncologist, 2011
- The ethical use of mandatory research biopsiesNature Reviews Clinical Oncology, 2011
- Ethics of Mandatory Research Biopsy for Correlative End Points Within Clinical Trials in OncologyJournal of Clinical Oncology, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- Performance of Biopsies in Clinical ResearchJournal of Clinical Oncology, 2007
- Are We Taking Without Giving in Return? The Ethics of Research-Related Biopsies and the Benefits of Clinical Trial ParticipationJournal of Clinical Oncology, 2006
- Impact and Perceptions of Mandatory Tumor Biopsies for Correlative Studies in Clinical Trials of Novel Anticancer AgentsJournal of Clinical Oncology, 2006